insiders

On 3 July 2016, a new standardized EU-regime to prevent market abuse took effect, including new rules on disclosure of inside information, insider lists and restrictions on dealings by persons discharging managerial responsibilities. The scope of MAR is broader than the previous regime, which means that issuers listed on Nasdaq First North Growth Market now find themselves subject to these rules.

According to MAR, neither insiders nor their shareholdings need to be reported or published on the issueru2019s website. An obligation to report transactions applies to persons discharging managerial responsibilities, and their associated persons, but only when such transactions reach and/or surpass the limit value of EUR 5,000 in one and the same calendar year.

Transactions that have been reported by any person discharging managerial responsibilities (so-called PDMR transactions) are listed by Finansinspektionen (the Swedish Financial Supervisory Authority).

Link to the register of PDMR transactions kept by the Swedish Financial Supervisory Authority.

General information on the new regulation is available on the website of the Swedish Financial Supervisory Authority and can be reached by this link.

What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram